Porträt Prof. Dr. Kopka, Klaus; FWP

Prof. Dr. Klaus Kopka

Director Institute of Radio­pharma­ceutical Cancer Research
Phone: +49 351 260 2060

Prof. Dr. Cornelius Fischer

Head of Department
Reactive Transport
Phone: +49 351 260 4660

Katrin Gerstner

Secretary Reactive Transport / Neuroradiopharmaceuticals
Research Site Leipzig
Phone: +49 351 260 4601

Courses on radiation protection

Our courses on radiation protection are held in German only - please see the German version.

Leipzig Research Center of the HZDR

In Leipzig, scientists at the Helmholtz Center Dresden-Rossendorf work on topics in the research fields of energy and health. They develop radiolabeled substances and use them to elucidate processes.

Reactive Transport Department


Our research aims at a fundamental and mechanistic understanding of reactive transport processes in complex porous solids and in the geosphere. We analyze the surface reactivity and kinetics of fluid-solid reactions, as well as the transport behavior of solutes and particles. Radiotracer methods enable temporally and spatially resolved, non-invasive analysis of reactive transport at the pore scale and above. Our results find application in the quantitative prediction of the long-term behavior of reactive materials.

The department is part of the HZDR Institute for Resource Ecology.

Neuroradiopharmaceuticals Department

Aufnahme mit Kleintier-PET-MR (Bild | PET-Aufnahmen: André Künzelmann | Mathias Kranz)

The "Neuroradiopharmaceuticals" department designs and develops radioactive molecular probes to help detect brain diseases such as Alzheimer's dementia, depression or brain tumors as early as possible. These so-called radiotracers are taken from animal models to application in humans in order to better understand the causes of cancer and neurodegenerative diseases and to be able to treat them in a targeted manner.

There are close cooperations with the Medical Faculty or the University Hospital Leipzig and the Institute of Pharmacy of the University of Leipzig.

The department is part of the HZDR Institute for Radiopharmaceutical Cancer Research.